Physician

Tom Yang, M.D.

According to 2025 Medicare claims, Tom Yang, M.D. (NPI: 1548346695) practices nephrology in the Visalia, CA market, with the plurality of this provider's patient population coming from Tulare, CA. This provider's primary affiliated billing organization is TOM YANG MD INC (NPI: 1417101908; TIN: 26-3689376) and primary practice location at 93277-2641.

Yang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,185 traditional Medicare patients, billed 9,722 HCPCS/CPT codes, and received $975,364 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 5,682 prescription claims across 889 beneficiaries totaling $1,636,578 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 99 claims. Open Payments data shows 149 records totaling $2,785. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,474,176 and ending at $1,636,578. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $3,697 to $4,531.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	979	11,517	$769,038
2016	1,031	10,683	$815,375
2017	949	10,667	$760,598
2018	1,080	12,619	$839,756
2019	1,096	11,029	$805,427
2020	1,111	8,901	$802,734
2021	1,132	7,018	$842,968
2022	1,078	6,673	$819,795
2023	1,147	7,565	$879,449
2024	1,185	9,722	$975,364

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	522	7,787	$1,474,176
2016	541	8,209	$1,434,367
2017	536	7,638	$1,467,590
2018	610	7,776	$1,010,656
2019	630	6,825	$1,032,343
2020	628	5,965	$1,102,523
2021	602	5,194	$1,289,365
2022	672	5,984	$1,728,373
2023	794	6,851	$2,234,610
2024	889	5,682	$1,636,578

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	23	122	$5,730
2016	N/R	169	$9,125
2017	N/R	142	$8,847
2018	N/R	77	$5,859
2019	N/R	14	$350
2020	N/R	11	$211
2021	N/R	30	$802
2022	N/R	59	$1,072
2023	N/R	194	$5,200
2024	N/R	99	$2,168

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	670	1,274	$106
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	179	179	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	745	1,277	$78
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	185	1,301	$67
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	717	1,246	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	195	5,946	$433,806
Farxiga	Dapagliflozin Propanediol	477	20,463	$369,347
Lokelma	Sodium Zirconium Cyclosilicate	174	5,860	$123,380
Procrit	Epoetin Alfa	62	1,785	$119,909
Ozempic	Semaglutide	82	3,010	$81,152

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	14	$972
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	32	$401
J7520	Sirolimus, oral, 1 mg	N	N/R	11	$398
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	20	$282
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$109

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	149	$2,785	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tom Yang, M.D.?

Tedicare shows public-source Medicare data for Tom Yang, M.D. (NPI 1548346695), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tom Yang, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Tom Yang, M.D.?

Tom Yang, M.D. is linked to TOM YANG MD INC (billing NPI 1417101908) in the available physician profile data.

Does Tom Yang, M.D. have Open Payments data?

Tom Yang, M.D. has 149 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.